GlassScriptPhysician profile
Farah Wani
NPI 1427687771
$489.11
in general payments reported to CMS, 2019-2025
15 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $124 · 2024: $76.48 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $93.06 | 2024-2025 | Resmetirom, Rezdiffra |
| Novo Nordisk INC | $92.35 | 2023 | Ozempic, Rybelsus |
| Amgen INC. | $45.47 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $40.10 | 2025 | Jardiance, Zepbound, Mounjaro |
| Eisai INC. | $30.11 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $29.84 | 2024-2025 | Eliquis |
| Organon LLC | $20.91 | 2025 | Nexplanon |
| Fisher & Paykel Healthcare INC | $20.40 | 2025 | Fisher & Paykel Healthcare |
| Phathom Pharmaceuticals, INC. | $19.17 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $18.95 | 2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $16.59 | 2025 | Airsupra |
| Pfizer INC. | $16.33 | 2025 | |
| Abbvie INC. | $16.05 | 2023 | Dalvance |
| Novartis Pharmaceuticals Corporation | $15.47 | 2023 | |
| Glaxosmithkline, LLC. | $14.31 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Wani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.